Literature DB >> 3026967

Activity of nedocromil sodium in mast-cell-dependent reactions in the rat.

P A Riley, M E Mather, R W Keogh, R P Eady.   

Abstract

Nedocromil sodium, a pyranoquinoline dicarboxylic acid derivative which differs structurally and physiochemically from sodium cromoglycate, was nonetheless shown to be effective in classical models of anti-allergic activity in the rat. These models, based on immediate hypersensitivity reactions in the passively sensitized rat, involve release of mediators from mast cells following cross-linking of membrane-bound IgE antibodies by specific antigen. In this system, nedocromil sodium exhibited a similar profile of activity to that of sodium cromoglycate. Whilst not predictive for therapeutic activity, rat models of immediate hypersensitivity are believed to reflect one component of obstructive airways disease. The results suggest that nedocromil sodium is worthy of clinical evaluation in this indication.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3026967     DOI: 10.1159/000234299

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  10 in total

Review 1.  Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

2.  The abnormal in vitro response to aspirin of platelets from aspirin-sensitive asthmatics is inhibited after inhalation of nedocromil sodium but not of sodium cromoglycate.

Authors:  C H Marquette; M Joseph; A B Tonnel; H Vorng; P Lassalle; A Tsicopoulos; A Capron
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

3.  Effect of nedocromil sodium on the beta-adrenergic response of human polymorphonuclear leucocytes.

Authors:  W W Busse; B Randlev; M Arbabian; A Ruoho
Journal:  Drugs       Date:  1989       Impact factor: 9.546

4.  Development of preclinical models for testing antiasthma drugs.

Authors:  T S Orr
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 5.  Respiratory and allergic disease. I.

Authors:  K F Chung; P J Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-02

6.  Nedocromil sodium inhibits antigen-induced contraction of human lung parenchymal and bronchial strips, and the release of sulphidopeptide-leukotriene and histamine from human lung fragments.

Authors:  F E Napier; M A Shearer; D M Temple
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

7.  An essential role for mast cells as modulators of neutrophils influx in collagen-induced arthritis in the mouse.

Authors:  Tatiana Aparecida Pimentel; André Luiz Franco Sampaio; Fulvio D'Acquisto; Mauro Perretti; Sonia Maria Oliani
Journal:  Lab Invest       Date:  2010-08-16       Impact factor: 5.662

8.  Double blind, placebo controlled study of nedocromil sodium in asthma.

Authors:  L Armenio; G Baldini; M Bardare; A Boner; R Burgio; G Cavagni; M La Rosa; F Marcucci; M Miraglia del Giudice; M R Pulejo
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

Review 9.  Long-term management of reversible obstructive airways disease in adults.

Authors:  A Lurie; F D Vlastos; D J Dusser; G Strauch; J Marsac
Journal:  Lung       Date:  1990       Impact factor: 2.584

10.  Nedocromil sodium prevents in vivo generation of the eosinophilotactic substance induced by PAF but fails to antagonize its effects.

Authors:  P M e Silva; M A Martins; H C Castro-Faria-Neto; P T Bozza; A L Pires; R S Cordeiro; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.